AnaBios provides unparalleled access to human tissue and cells for drug discovery, creating the unprecedented opportunity to develop safer, more effective drugs while reducing time-to-market and clinical development costs.

In close partnership with organ donation organizations, hospitals and transplant centers, AnaBios has developed proprietary processes for functional ex vivo human platforms that redefine the concept of “First in Human” studies and bring true human biology to early pre-clinical discovery.

Our functional assays cover a wide breadth of cardiovascular, central nervous system (CNS) and peripheral nervous system (PNS) biology.  Whether your team is looking to identify new therapeutics in heart failure, cardiovascular disorders, pain, itch, spinal cord ailments and other disease states, or looking to ensure cardiac and neuronal safety, let us bring native human biology into your pipeline at the earliest stages to ensure safety and efficacy while avoiding costly late-stage failures.

Similarly, if you are experiencing pipeline or clinical delays due to unanticipated adverse events, AnaBios can help fast track your programs for approval utilizing our human tissue platforms.